KalVista Pharmaceuticals マネジメント

マネジメント基準チェック /24

KalVista Pharmaceuticalsの CEO はBen Palleikoで、 Mar2024年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 6.77Mで、 8.6%給与と91.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.62%を直接所有しており、その価値は€ 2.96M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と3.7年です。

主要情報

Ben Palleiko

最高経営責任者

US$6.8m

報酬総額

CEO給与比率	8.6%
CEO在任期間	less than a year
CEOの所有権	0.6%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

KalVista Pharmaceuticals の収益と比較して、Ben Palleiko の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jul 31 2024	n/a	n/a	-US$142m
Apr 30 2024	US$7m	US$580k	-US$127m
Jan 31 2024	n/a	n/a	-US$108m
Oct 31 2023	n/a	n/a	-US$101m
Jul 31 2023	n/a	n/a	-US$95m
Apr 30 2023	US$2m	US$515k	-US$93m
Jan 31 2023	n/a	n/a	-US$91m
Oct 31 2022	n/a	n/a	-US$92m
Jul 31 2022	n/a	n/a	-US$89m
Apr 30 2022	US$3m	US$490k	-US$82m
Jan 31 2022	n/a	n/a	-US$73m
Oct 31 2021	n/a	n/a	-US$61m
Jul 31 2021	n/a	n/a	-US$52m
Apr 30 2021	US$1m	US$435k	-US$46m
Jan 31 2021	n/a	n/a	-US$38m
Oct 31 2020	n/a	n/a	-US$37m
Jul 31 2020	n/a	n/a	-US$33m
Apr 30 2020	US$1m	US$435k	-US$29m
Jan 31 2020	n/a	n/a	-US$31m
Oct 31 2019	n/a	n/a	-US$26m
Jul 31 2019	n/a	n/a	-US$23m
Apr 30 2019	US$2m	US$366k	-US$21m
Jan 31 2019	n/a	n/a	-US$13m
Oct 31 2018	n/a	n/a	-US$14m
Jul 31 2018	n/a	n/a	-US$16m
Apr 30 2018	US$821k	US$340k	-US$16m

報酬と市場: Benの総報酬 ($USD 6.77M ) は、 German市場 ($USD 1.03M ) の同規模の企業の平均を上回っています。

報酬と収益: Benの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Ben Palleiko (58 yo)

less than a year

在職期間

US$6,772,197

報酬

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Benjamin Palleiko	CEO & Director	less than a year	US$6.77m	0.62% € 3.0m
Christopher Yea	Chief Development Officer	9yrs	US$1.37m	0.21% € 998.8k
Paul Audhya	Chief Medical Officer	3.5yrs	US$1.83m	0.22% € 1.0m
Brian Piekos	Chief Financial Officer	less than a year	データなし	データなし
Ryan Baker	Head of Investor Relations	no data	データなし	データなし
Brian Krex	General Counsel	no data	データなし	データなし
Jarrod Aldom	Vice President of Corporate Communications	no data	データなし	データなし
Rachel Morten	Senior Vice President of Regulatory Affairs & QA	no data	データなし	データなし
Michael Smith	Senior Vice President of Development	5.5yrs	データなし	データなし
Nicole Sweeny	Chief Commercial Officer	1.3yrs	データなし	データなし
Stephen Donnelly	Director of Finance and Company Secretary	no data	データなし	データなし

2.4yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: 4XC1の経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Benjamin Palleiko	CEO & Director	less than a year	US$6.77m	0.62% € 3.0m
Edward Unkart	Independent Director	9.9yrs	US$136.60k	0% € 0
Brian J. Pereira	Independent Chairman	5.8yrs	US$161.60k	0% € 0
Nancy Stuart	Independent Director	3.7yrs	US$136.60k	0% € 0
William Fairey	Independent Director	less than a year	US$143.78k	データなし
Tomas Kiselak	Board Observer	9.3yrs	データなし	データなし
Patrick Treanor	Independent Director	2.5yrs	US$124.10k	0% € 0

3.7yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 4XC1の取締役会は経験豊富であると考えられます ( 3.7年の平均在任期間)。

KalVista Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. Announces Board Changes

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Recent updates

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc.

Forecast to breakeven in 2027

KalVista Pharmaceuticals, Inc. Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

New major risk - Share price stability

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

New major risk - Financial position

Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

No longer forecast to breakeven

New minor risk - Profitability

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024

Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

New minor risk - Profitability

New major risk - Financial position

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

No longer forecast to breakeven

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee

Revenue misses expectations

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

New 90-day low: €12.50

Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus

Revenue misses expectations

Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020

New 90-day high: €16.20

KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial

New 90-day high: €14.60

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

New 90-day high: €11.90

New 90-day high - €11.60

First quarter earnings released

New 90-day high - €11.50

マネジメント基準チェック /24